Revelation Biosciences, Inc. (NASDAQ:REVB) Shares Shorted: Short Interest Up 93.7% in October

Revelation Biosciences, Inc. (NASDAQ:REVB – Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 12,792 shares, an increase of 93.7% from the October 15th total of 6,605 shares. Based on an average trading volume of 39,572 shares, the days-to-cover ratio is currently 0.3 days. Currently, 2.0% of the shares of the stock are sold short.

Revelation Biosciences Price Performance

Shares of Revelation Biosciences stock traded down $0.05 during trading on Friday, reaching $4.33. 6,579 shares of the stock traded hands, compared to its average volume of 27,757. The company has a market capitalization of $2.95 million, a price-to-earnings ratio of -0.10 and a beta of -0.13. The business has a fifty day simple moving average of $5.16 and a two-hundred day simple moving average of $7.42. Revelation Biosciences has a 52-week low of $3.08 and a 52-week high of $40.60.

Revelation Biosciences (NASDAQ:REVB – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($5.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($6.16) by $0.24. On average, research analysts predict that Revelation Biosciences will post -24.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, Revelation Biosciences has an average rating of “Sell”.

Get Our Latest Stock Report on REVB

About Revelation Biosciences

(Get Free Report)

Revelation Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapies that stimulate the body’s innate immune system. The company’s research is centered on immunologic treatments intended to help prevent or manage infectious and other acute diseases. Its lead development programs are based on Gemini, a proprietary toll-like receptor 4 agonist designed to activate innate immune responses. Revelation has investigated intranasal formulations, including REVTx-99, for potential use against respiratory viral infections, as well as other candidates aimed at addressing serious medical conditions such as sepsis.

See Also

Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.